Compare
Orasure Technologies Inc vs Beta Bionics, Inc. vs NeuroPace Inc vs Xtant Medical Holdings, Inc.
| Latest fiscal year | Orasure Technologies Inc OSUR | Beta Bionics, Inc. BBNX | NeuroPace Inc NPCE | Xtant Medical Holdings, Inc. XTNT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $115.02M | $100.25M | $99.99M | $133.93M |
| Revenue growth (YoY) | -38.1% | +53.9% | +25.1% | +14.2% |
| Gross margin | 41.9% | 55.4% | 77.2% | 62.9% |
| Operating margin | -62.6% | -71.5% | -16.3% | 5.4% |
| Net margin | -59.8% | -73.0% | -21.5% | 3.7% |
| Net income | -$68.73M | -$73.20M | -$21.46M | $4.97M |
| EPS (Diluted) | -$0.94 | -$1.81 | -$0.66 | $0.03 |
| Operating cash flow | -$49.02M | -$50.92M | -$11.01M | $12.55M |
| Free cash flow | -$53.22M | -$56.22M | -$11.34M | $10.16M |
| Cash & equivalents | $199.28M | $31.58M | $21.69M | $17.05M |
| Total assets | $403.17M | $328.74M | $105.56M | $94.14M |
| Total liabilities | $62.34M | $41.13M | $86.53M | $43.19M |
| Shareholders' equity | $340.83M | $287.61M | $19.03M | $50.95M |
| Return on year-end equity | -20.2% | -25.5% | -112.8% | 9.8% |
| Shares outstanding | 70.39M | 44.36M | 33.57M | 140.04M |
Revenue, most recent five fiscal years
| Fiscal year | Orasure Technologies Inc | Beta Bionics, Inc. | NeuroPace Inc | Xtant Medical Holdings, Inc. |
|---|---|---|---|---|
| Latest | $115.02M Ended 2025-12-31 | $100.25M Ended 2025-12-31 | $99.99M Ended 2025-12-31 | $133.93M Ended 2025-12-31 |
| 1 year earlier | $185.83M Ended 2024-12-31 | $65.12M Ended 2024-12-31 | $79.91M Ended 2024-12-31 | $117.27M Ended 2024-12-31 |
| 2 years earlier | $405.47M Ended 2023-12-31 | $11.99M Ended 2023-12-31 | $65.42M Ended 2023-12-31 | $91.30M Ended 2023-12-31 |
| 3 years earlier | $387.48M Ended 2022-12-31 | n/a | $45.52M Ended 2022-12-31 | $57.97M Ended 2022-12-31 |
| 4 years earlier | $233.67M Ended 2021-12-31 | n/a | $45.18M Ended 2021-12-31 | $55.26M Ended 2021-12-31 |